Clinical-stage gene therapy company Genprex Inc (NASDAQ: GNPX) announced on Monday that positive preclinical data on its lead candidate, Reqorsa Gene Therapy, will be presented at the 2024 EORTC-NCI-AACR Symposium, taking place from 23-25 October 2024 in Barcelona.
The data focuses on Reqorsa's potential as a treatment for Ras inhibitor-resistant lung cancer, mesothelioma and glioblastoma.
Collaborators, including the University of Texas MD Anderson Cancer Center and New York University Langone Health, will showcase studies demonstrating that Reqorsa's TUSC2 gene therapy overcomes resistance in KRAS mutant lung cancer and suppresses tumour growth in mesothelioma and glioblastoma. Two provisional patent applications have been filed based on these findings.
Reqorsa, which uses Genprex's Oncoprex Delivery System, specifically targets cancer cells with the TUSC2 gene, delivering promising preclinical results.
BioNTech and Bristol Myers Squibb partner to co-develop bispecific antibody for solid tumours
Taiho Oncology and Cullinan Therapeutics report REZILIENT1 Phase 1/2 data
BioCryst showcases consistent efficacy of ORLADEYO across all age groups in HAE treatment
Lunit presenting 12 studies at ASCO 2025
Dizal to present promising data in CLL, DLBCL and EGFR-Mutant NSCLC at ASCO 2025
Pfizer to present Phase 1 study design on MesoC2 at 2025 ASCO Annual Meeting
Accropeutics reports positive data from Phase 2 psoriasis treatment trial
Lupin to adopt Honeywell's low-emission propellant in next-generation inhalers
Zai Lab secures FDA Fast Track designation for ZL-1310 to treat small cell lung cancer
ArkBio reports positive Phase II results in idiopathic pulmonary fibrosis
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software
Cumberland Pharmaceuticals partners Qureight for idiopathic pulmonary fibrosis treatment research